ClinicalTrials.Veeva

Menu
O

Oakland Hills Dermatology | Auburn Hills, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lebrikizumab
Rocatinlimab
Spesolimab
bermekimab
Ritlecitinib
Litifilimab
DS-7011a
Povorcitinib
Amlitelimab
Dupilumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 21 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo
Locations recently updated

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab
Locations recently updated

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting
Vitiligo
Drug: Upadacitinib
Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Invitation-only
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Povorcitinib
Drug: Placebo

This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous stud...

Active, not recruiting
Generalized Pustular Psoriasis
Drug: Spesolimab

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).The purpose of thi...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab

Trial sponsors

Lilly logo
Amgen logo
AbbVie logo
Boehringer Ingelheim logo
A
Biogen logo
Celldex Therapeutics logo
Daiichi Sankyo logo
H
Incyte logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems